185 related articles for article (PubMed ID: 1982639)
1. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.
Beck WT
Cancer Treat Rev; 1990 Dec; 17 Suppl A():11-20. PubMed ID: 1982639
[TBL] [Abstract][Full Text] [Related]
2. Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II.
Beck WT
Bull Cancer; 1990; 77(11):1131-41. PubMed ID: 1980425
[TBL] [Abstract][Full Text] [Related]
3. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype.
Eijdems EW; Borst P; Jongsma AP; de Jong S; de Vries EG; van Groenigen M; Versantvoort CH; Nieuwint AW; Baas F
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3498-502. PubMed ID: 1348862
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
6. [Atypical MDR].
Yokomizo A; Taniguchi K; Hasegawa S; Abe T; Kubo T; Makino Y; Wada M; Kohno K; Kuwano M
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1123-9. PubMed ID: 7913311
[TBL] [Abstract][Full Text] [Related]
7. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
8. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
10. Cellular resistance to anthracyclines.
Nielsen D; Maare C; Skovsgaard T
Gen Pharmacol; 1996 Mar; 27(2):251-5. PubMed ID: 8919638
[TBL] [Abstract][Full Text] [Related]
11. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
12. Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.
Center MS
Cytotechnology; 1993; 12(1-3):109-25. PubMed ID: 7765322
[TBL] [Abstract][Full Text] [Related]
13. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
15. Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin.
Versantvoort CH; Broxterman HJ; Feller N; Dekker H; Kuiper CM; Lankelma J
Int J Cancer; 1992 Apr; 50(6):906-11. PubMed ID: 1348241
[TBL] [Abstract][Full Text] [Related]
16. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.
Chen YN; Mickley LA; Schwartz AM; Acton EM; Hwang JL; Fojo AT
J Biol Chem; 1990 Jun; 265(17):10073-80. PubMed ID: 1972154
[TBL] [Abstract][Full Text] [Related]
17. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro.
Hill BT; Deuchars K; Hosking LK; Ling V; Whelan RD
J Natl Cancer Inst; 1990 Apr; 82(7):607-12. PubMed ID: 1968980
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents.
Mickley LA; Bates SE; Richert ND; Currier S; Tanaka S; Foss F; Rosen N; Fojo AT
J Biol Chem; 1989 Oct; 264(30):18031-40. PubMed ID: 2572588
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Shabbits JA; Mayer LD
Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
